Overview

Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age

Status:
Withdrawn
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Demonstrate the safety and efficacy of Kabiven compared to standard parenteral nutrition (PN) administered via central vein in pediatric patients (2 to 16 years of age) requiring PN to meet nutritional needs.
Phase:
Phase 4
Details
Lead Sponsor:
Fresenius Kabi